InsidersTradesSigma
BeOne Medicines Ltd. Stock: price and management transactions · United States · SEC (Form 4)
Follow the BeOne Medicines Ltd. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, BeOne Medicines Ltd. has logged 116 reports. Market capitalisation: €31.4bn. The latest transaction was reported on 25 June 2026 (Cession). Among the most active insiders: OYLER JOHN. All data is openly available.
BeOne Medicines Ltd., listed on XNAS in the Healthcare & Pharma sector, reported a total of 94 insider trading declarations in the past 90 days. The total amount sold by insiders reached approximately 991,029 euros, while no purchases were reported. The top insiders include Oyler John Victor, a Director, with sales totaling about 415,624 euros across 9 declarations, and BAKER BROS. ADVISORS LP, also a Director, with 6 declarations totaling approximately 225,435 euros. Lee Chan Henry, the SVP and General Counsel, reported sales of about 159,097 euros over 10 declarations. Significant sales by Oyler John Victor include amounts of 147,912 euros on June 10, 107,831 euros on June 18, and 104,611 euros on June 25. Other notable sales include Lee Chan Henry's 88,049 euros on May 15 and several sales around 56,479 euros by various directors on May 27.
Auto-generated summary, refreshed daily.Updated 5d ago
116
Insider Decl.
0
Thresholds
·
10 ops.
Buy Volume
€4m
60 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BeOne Medicines Ltd. Strong Buy (bullish), based on 27 analysts. Average price target: US$413.05.
44Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 14,023 of 25,936 companies
49.6
score / 100
Value31
Quality68
FCF yld2.7%
Earn yld0.9%
EV/EBITDA52.7x
ROE12%
Gross mgn87%
Net mgn5.4%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 25 June 2026
Declarations116 total
1,800 sharesAmerican Depositary SharesSEC:0001042047-26-000007:0
1,290 sharesAmerican Depositary SharesSEC:0001042047-26-000007:1
320 sharesAmerican Depositary SharesSEC:0001042047-26-000007:2
1,292 sharesAmerican Depositary SharesSEC:0001739452-26-000008:0
20,904 sharesShareXHKGHKEX:DA20260625E00176
83,512 sharesShareXHKGHKEX:DA20260625E00169
42,900 shares@ €2.43850.0004% mcap25.2% of flowShareXHKGHKEX:DA20260625E00170
1,650 sharesAmerican Depositary SharesSEC:0001042047-26-000006:0
1,710 sharesAmerican Depositary SharesSEC:0001042047-26-000006:1
333 sharesAmerican Depositary SharesSEC:0001042047-26-000006:2
1,357 sharesAmerican Depositary SharesSEC:0001739452-26-000007:0
590 sharesAmerican Depositary SharesSEC:0001980648-26-000015:0
21,554 sharesShareXHKGHKEX:DA20260618E00037
88,907 sharesShareXHKGHKEX:DA20260618E00038
48,009 shares@ €2.24610.0004% mcap25.9% of flowShareXHKGHKEX:DA20260618E00039
18,980 sharesShareXHKGHKEX:DA20260616E00536
Ideal exit: 8 Mar 2027 (T+270)
25,302 sharesShareXHKGHKEX:DA20260616E00535
487,708 sharesShareXHKGHKEX:DA20260616E00364
293,384 sharesShareXHKGHKEX:DA20260616E00230
Ideal exit: 8 Mar 2027 (T+270)
18,980 sharesShareXHKGHKEX:DA20260616E00304
Ideal exit: 8 Mar 2027 (T+270)
18,980 sharesShareXHKGHKEX:DA20260616E00277
Ideal exit: 8 Mar 2027 (T+270)
1,234,350 sharesShareXHKGHKEX:DA20260616E00163
Ideal exit: 8 Mar 2027 (T+270)
18,980 sharesShareXHKGHKEX:DA20260616E00266
Ideal exit: 8 Mar 2027 (T+270)
25 of 116 declarations
About BeOne Medicines Ltd.
BeOne Medicines Ltd. is a global biopharmaceutical company listed on the NASDAQ (United States) under the ticker ONC, with additional listings in Hong Kong and Shanghai. The company, formerly known as BeiGene, completed a name change and redomiciliation on May 27, 2025, moving its place of incorporation from the Cayman Islands to Switzerland while keeping its Nasdaq Global Select Market listing intact. For international investors, this means BeOne is a U.S.-listed oncology company with a Swiss legal domicile and a globally distributed operating footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651308/000110465925053039/tm2515777d11_posasr.htm)) Founded in 2010 by John V. Oyler and Xiaodong Wang, BeOne was built around a clear mission: to develop innovative cancer therapies and make them more accessible across global markets. The company’s operational footprint spans major hubs including San Carlos, California; Cambridge, Massachusetts; and Basel, Switzerland, alongside manufacturing and R&D capabilities in the United States, China, Europe, and Latin America. BeOne also highlights a broad global research network, with clinical development and commercial activities across multiple continents. ([beonemedicines.com](https://beonemedicines.com/about/history/?utm_source=openai)) BeOne is primarily an oncology-focused business. Its commercial foundation rests on two key medicines: BRUKINSA (zanubrutinib), a BTK inhibitor used in several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy used in solid tumors and hematologic indications. Beyond these marketed products, the company is advancing a broad pipeline that spans blood cancers, lung cancer, breast/gynecological cancers, gastrointestinal cancers, and certain rare cancers. BeOne states that it has more than 30 investigational medicines in development, underscoring a pipeline-driven growth model rather than a narrow single-asset profile. ([beonemedicines.com](https://beonemedicines.com/science/medicines/?utm_source=openai)) From a competitive perspective, BeOne operates in a highly crowded oncology landscape against major global pharma groups and specialist biotech peers. Its differentiation lies in an integrated development model, a wide geographic commercialization strategy, and a stated focus on improving patient access. The company reports regulatory approvals for its internally developed medicines in more than 75 countries, which gives it meaningful international reach and supports the view that it is building a global oncology platform rather than a purely regional business. ([beonemedicines.com](https://beonemedicines.com/about/our-company/faqs/?utm_source=openai)) Recent developments have been constructive. In February 2026, BeOne reported full-year 2025 revenue of $5.3 billion and highlighted strong global momentum for BRUKINSA. In May 2026, the company announced U.S. FDA approval of BEQALZI (sonrotoclax), and it also received FDA Priority Review for TEVIMBRA in a HER2-positive first-line indication. These updates reinforce the company’s clinical execution and regulatory momentum, both of which are central to the investment case in oncology biotech. ([ir.beonemedicines.com](https://ir.beonemedicines.com/news/beone-medicines-announces-fourth-quarter-and-full-year-2025-financial-results-highlighting-global-success-of/6559b41c-7beb-45ca-bc76-5e1c9cdb26cc?utm_source=openai))
